Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA Library Screening Platform
Development of a high-performance tool set for human and mouse genetic screens to enable enhanced drug discovery underway NEWS PROVIDED BY Cellecta, Inc. 26 Jan, 2017, 08:40 ET SHARE THIS ARTICLE MOUNTAIN VIEW, Calif., Jan. 26, 2017 /PRNewswire/ — Cellecta, Inc. today announced the receipt of Phase II SBIR grant funds from the National Institute of... Read more